Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

Moderna has been hit by massive insider selling over the last couple of years. The stock has a 52-week high of over $170 while Moderna entered 2020 trading below $20, making insiders more likely ...

The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.

Kate Cronin, who took the marketing reins at Moderna in 2021 as it was skyrocketing to global renown for its COVID-19 vaccine, is stepping down from her post. Cronin joined Moderna in the summer ...